Michael Barbella, Managing Editor03.03.23
Neuronetics Inc. has appointed Joseph H. Capper to its Board of Directors and as a member of the Audit Committee.
“Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," Board Chairman Rob Cascella said. “His depth of experience with public companies and his passion for innovative medical technologies will further strengthen our Board, benefit our company, and help the patients served by our mental health providers.”
Capper brings nearly 30 years of medtech and life sciences experience to the company. Most recently, he served as president and CEO of BioTelemetry Inc., the successor to CardioNet Inc. and Home Diagnostics Inc. Prior to Home Diagnostics, Capper was president and CEO of CCS Medical Inc., a private company. Earlier, Capper spent nine years with Bayer Corporation, ultimately becoming national sales director of the Diabetic Products Division.
Capper also has a distinguished service record, having served in the U.S. Navy as a combat aviator and later as a congressional liaison. He earned his undergraduate degree in accounting from West Chester University and an MBA in international finance from George Washington University.
“The accelerating decline of mental health in the wake of the pandemic makes Neuronetics’ technology more relevant than ever,” Capper stated. “I am impressed by the organization’s mission to transform neurohealth and its passion for that purpose. I look forward to contributing to the company’s future success.”
Neuronetics Inc. developed the NeuroStar Advanced Therapy for Mental Health, a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. NeuroStar is cleared by the U.S. Food and Drug Administration for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is a transcranial magnetic stimulation (TMS) treatment for MDD in adults with more than 5 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry.
“Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," Board Chairman Rob Cascella said. “His depth of experience with public companies and his passion for innovative medical technologies will further strengthen our Board, benefit our company, and help the patients served by our mental health providers.”
Capper brings nearly 30 years of medtech and life sciences experience to the company. Most recently, he served as president and CEO of BioTelemetry Inc., the successor to CardioNet Inc. and Home Diagnostics Inc. Prior to Home Diagnostics, Capper was president and CEO of CCS Medical Inc., a private company. Earlier, Capper spent nine years with Bayer Corporation, ultimately becoming national sales director of the Diabetic Products Division.
Capper also has a distinguished service record, having served in the U.S. Navy as a combat aviator and later as a congressional liaison. He earned his undergraduate degree in accounting from West Chester University and an MBA in international finance from George Washington University.
“The accelerating decline of mental health in the wake of the pandemic makes Neuronetics’ technology more relevant than ever,” Capper stated. “I am impressed by the organization’s mission to transform neurohealth and its passion for that purpose. I look forward to contributing to the company’s future success.”
Neuronetics Inc. developed the NeuroStar Advanced Therapy for Mental Health, a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. NeuroStar is cleared by the U.S. Food and Drug Administration for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is a transcranial magnetic stimulation (TMS) treatment for MDD in adults with more than 5 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry.